Athena Athena

X
[{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"$3.2 million","newsHeadline":"Aradigm Announces Entering into an Asset Purchase Agreement with Grifols, S.A.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Aradigm

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Grifols, S.A.will acquire the Company’s assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof.

            Lead Product(s): Ciprofloxacin

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Grifols International

            Deal Size: $6.2 million Upfront Cash: $3.2 million

            Deal Type: Acquisition February 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY